March 24, 2026 -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck, known as MSD outside the US and Canada, to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient’s somatic genomics platform technology. Somatic genetic mutations naturally accumulate over a lifetime, resulting in trillions of different genomes within an individual.

March 24, 2026 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no saf

-- Additional data from RSV re-vaccination trial demonstrates trend of approximately 60-80% higher RSV neutralizing antibodies (nAbs) for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) in older adults who previously received an initial dose of AREXVY -- -- Re-vaccination with Clover's RSV vaccine boosted RSV nAbs to approximately 120-135% of the peak levels observed after an initial dose of AREXVY (cross-trial comparison) -- -- Results further strengthen profile of potential best

Kalohexis' lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in advanced cancers 710GO has shown healthier, more durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists March 19, 2026 -- Endevica Bio, a privately-held company developing first-in-class synthetic peptidomimetics, toda

Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity. In previous clinical studies, taldefgrobep produced meaningful reductions in fat mass while increasin

The new alliance has launched a multi-agent AI framework to support faster, data-driven decisions in cancer research. Agentic AI system achieves 15x faster insights with over 90% accuracy. March 19, 2026--Globant (NYSE: GLOB), a digitally native company that helps organizations thrive in a digital and AI-powered future, and PharmaMar, world leader in the discovery, development and commercialization of marine-derived anti-cancer drugs, today announced a new collaboration designed to speed up can

Financing co-led by Taiho Ventures and Arkin Bio Capital with significant participation from other new and existing investors Investment enables continued clinical development of T-Bolt™ therapies, including completion of CBX-250 Phase 1 trial and initiation of CBX-663 clinical trial Preclinical and translational updates on both programs to be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting Crossbow Therapeutics, Inc., a biotechnology company developing a

Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026 March 19, 2026 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces a positive update from the placebo-controlled, double-blind first-in-human Phase I study i

Funding to advance proprietary T-cell engager platforms and pipeline of highly differentiated T-cell engager therapies targeting solid tumors and autoimmune diseases Financing co-led by multiple top-tier financial investors, with participation from global investors including LAV and Eisai One of the largest seed financing rounds for a Chinese biotechnology company Excalipoint Therapeutics, a biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmun

March 17, 2026 -- Pharmacosmos today announced the initiation of a phase III, randomised, double-blind, placebo-controlled, multicentre clinical trial evaluating the efficacy and safety of trilaciclib in participants with limited-stage small cell lung cancer. The study is being conducted at clinical sites in the United States, EU and the United Kingdom. The trial will compare trilaciclib with placebo when administered prior to standard chemoradiotherapy and is designed to assess whether trilaci